DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Diagnostic & Testing Substances Manufacturers
- Sub-Industry: N/A
- Symbol: NASDAQ:DBVT
- CUSIP: N/A
- Web: www.dbv-technologies.com
- Market Cap: $2.11503 billion
- Outstanding Shares: 46,000,000
- 50 Day Moving Avg: $41.36
- 200 Day Moving Avg: $36.29
- 52 Week Range: $31.87 - $46.33
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.36
- P/E Growth: 0.00
- Annual Revenue: $11.21 million
- Price / Sales: 176.04
- Book Value: $4.58 per share
- Price / Book: 9.37
- EBIDTA: ($160,530,000.00)
- Debt-to-Equity Ratio: 0.02%
- Current Ratio: 9.39%
- Quick Ratio: 9.39%
- Average Volume: 126,041 shs.
- Beta: 1.53
- Short Ratio: 4.73
Frequently Asked Questions for DBV Technologies S.A. (NASDAQ:DBVT)
What is DBV Technologies S.A.'s stock symbol?
DBV Technologies S.A. trades on the NASDAQ under the ticker symbol "DBVT."
How were DBV Technologies S.A.'s earnings last quarter?
DBV Technologies S.A. (NASDAQ:DBVT) announced its quarterly earnings data on Thursday, March, 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.35. View DBV Technologies S.A.'s Earnings History.
Where is DBV Technologies S.A.'s stock going? Where will DBV Technologies S.A.'s stock price be in 2017?
8 analysts have issued twelve-month price targets for DBV Technologies S.A.'s stock. Their forecasts range from $46.00 to $54.00. On average, they anticipate DBV Technologies S.A.'s share price to reach $48.80 in the next twelve months. View Analyst Ratings for DBV Technologies S.A..
Who are some of DBV Technologies S.A.'s key competitors?
Some companies that are related to DBV Technologies S.A. include Akorn (AKRX), Taro Pharmaceutical Industries (TARO), Hikma Pharmaceuticals Plc (HKMPF), Mednax (MD), Integra LifeSciences Holdings Corporation (IART), ACADIA Pharmaceuticals (ACAD), Patterson Companies (PDCO), Mallinckrodt PLC (MNK), Opko Health (OPK), Clovis Oncology (CLVS), NuVasive (NUVA), ICU Medical (ICUI), Molina Healthcare (MOH), Portola Pharmaceuticals (PTLA), Sage Therapeutics (SAGE), Insulet Corporation (PODD), Cantel Medical Corp. (CMD) and FibroGen (FGEN).
Who are DBV Technologies S.A.'s key executives?
DBV Technologies S.A.'s management team includes the folowing people:
- Pierre-Henri Benhamou, Chairman of the Board, Chief Executive Officer
- David Schilansky, Chief Operating Officer
- Hugh A. Sampson M.D., Chief Scientific Officer
- Lucie Mondoulet, Director of Research
- Nathalie Donne, Director of Corporate Communication & Business Development
- Veronique Foutel, Director of Strategic Marketing
- Wence Agbotounou, Chief Clinical Trial Officer
- Bertrand Dupont, Industrial Director
- Pascale Ehouarn, Industrial Development and Production Director
- Laurent Martin, Director of Regulatory Affairs
Who owns DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (6.54%), Janus Henderson Group PLC (5.52%), Jennison Associates LLC (2.18%), Alliancebernstein L.P. (2.17%), TimesSquare Capital Management LLC (2.02%) and Oak Ridge Investments LLC (1.82%). View Institutional Ownership Trends for DBV Technologies S.A..
Who sold DBV Technologies S.A. stock? Who is selling DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, First Manhattan Co., TimesSquare Capital Management LLC, Oak Ridge Investments LLC, Emory University, Artisan Partners Limited Partnership, Goldman Sachs Group Inc. and Parametric Portfolio Associates LLC. View Insider Buying and Selling for DBV Technologies S.A..
Who bought DBV Technologies S.A. stock? Who is buying DBV Technologies S.A. stock?
DBV Technologies S.A.'s stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Jennison Associates LLC, Botty Investors LLC, Sectoral Asset Management Inc, Sit Investment Associates Inc., Airain ltd, Exane Asset Management and Alps Advisors Inc.. View Insider Buying and Selling for DBV Technologies S.A..
How do I buy DBV Technologies S.A. stock?
Shares of DBV Technologies S.A. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DBV Technologies S.A.'s stock price today?
MarketBeat Community Rating for DBV Technologies S.A. (NASDAQ DBVT)MarketBeat's community ratings are surveys of what our community members think about DBV Technologies S.A. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of DBV Technologies S.A. stock can currently be purchased for approximately $42.90.
Earnings History for DBV Technologies S.A. (NASDAQ:DBVT)Earnings History by Quarter for DBV Technologies S.A. (NASDAQ DBVT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for DBV Technologies S.A. (NASDAQ:DBVT)
2017 EPS Consensus Estimate: ($4.00)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for DBV Technologies S.A. (NASDAQ:DBVT)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for DBV Technologies S.A. (NASDAQ:DBVT)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for DBV Technologies S.A. (NASDAQ:DBVT)
Latest Headlines for DBV Technologies S.A. (NASDAQ:DBVT)
DBV Technologies S.A. (DBVT) Chart for Wednesday, August, 16, 2017